A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
一项针对复发/难治性多发性骨髓瘤患者的 I/II 期研究,评估缺氧激活前药 Evofosfamide 联合或不联合硼替佐米的疗效。
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-18-1325
Laubach, Jacob P; Liu, Chia-Jen; Raje, Noopur S; Yee, Andrew J; Armand, Philippe; Schlossman, Robert L; Rosenblatt, Jacalyn; Hedlund, Jacquelyn; Martin, Michael; Reynolds, Craig; Shain, Kenneth H; Zackon, Ira; Stampleman, Laura; Henrick, Patrick; Rivotto, Bradley; Hornburg, Kalvis T V; Dumke, Henry J; Chuma, Stacey; Savell, Alexandra; Handisides, Damian R; Kroll, Stew; Anderson, Kenneth C; Richardson, Paul G; Ghobrial, Irene M